Actively Recruiting
Aflibercept and Bevacizumab for Diabetic Maculopathies
Led by Al-Mustansiriyah University · Updated on 2025-09-19
102
Participants Needed
1
Research Sites
40 weeks
Total Duration
On this page
Sponsors
A
Al-Mustansiriyah University
Lead Sponsor
B
Baghdad Medical City
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to to evaluate the clinical outcomes following treatment with bevacizumab versus aflibercept. These outcomes include: * Functional changes: The visual outcomes achieved by testing visual acuity * Anatomical changes: macular thickness and edema by optical coherence tomography (OCT).
CONDITIONS
Official Title
Aflibercept and Bevacizumab for Diabetic Maculopathies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with type 2 diabetes mellitus
- Patients diagnosed with diabetic maculopathies, including focal and diffuse maculopathies, according to Early Treatment of Diabetic Retinopathy Study (ETDRS) criteria
- Patients with reduced or reducing vision (6/9-6/90) by visual acuity and significant foveolar thickening on OCT (more than 250 cm)
- Patients treated with intravitreal anti-VEGF therapy (aflibercept or bevacizumab) for three successive monthly injections
You will not qualify if you...
- Patients with type 1 diabetes mellitus
- Patients with type 2 diabetes on insulin therapy
- Patients treated with intravitreal anti-VEGF within the past 3 months or corticosteroids within 6 months
- Prior macular photocoagulation or photodynamic therapy
- Intraocular surgeries within 3 months
- Pregnant or nursing women
- History of thromboembolic events or cardiovascular complications from systemic VEGF inhibition
- Major surgery within the past year or planned in the next months
- Uncontrolled hypertension
- Known coagulation abnormalities or use of anticoagulant medication other than aspirin
- Hemorrhagic macular infarction
- Intraocular pressure above 25 mmHg
- Presence of iris neovascularization or vitreous hemorrhage
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Baghdad Medical City Complex
Baghdad, Iraq, 10001
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here